Skip to content

Author

Anna E. Howell

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A035: Co-targeting emergent vulnerabilities to overcome FOLFIRINOX resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with a five-year survival rate of just 13%. For the >80% of patients presenting with metastatic disease, standard-of-care systemic chemotherapies such as FOLFIRINOX or gemcitabine/nab-paclitaxel (GnP) inevitably induce resistance, frequently forci...

Brooke A. Pereira, Katie A. Gordon, Victoria M. Tyma et al. · 0 citations
Sep 2026

Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...

Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.